Ado-trastuzumab emtansine

Common Brands Actos
Drug Class
Controlled Substance Classification
Not a controlled medication
Generic Status
Lower-cost generic available
Prescription only
Allison Barnes, PharmD
Allison Barnes, PharmD
Read More
Medically reviewed by Allison Barnes, PharmD last update on 20/12/2023


Ado-trastuzumab emtansine, familiarly known as T-DM1, stands at the forefront of HER2-positive breast cancer treatment. This cutting-edge medication combines the precision of monoclonal antibodies with the potency of chemotherapy, representing a paradigm shift in therapeutic strategies. Approved by regulatory authorities, T-DM1 is a beacon of hope for patients facing both early-stage and metastatic breast cancer.

At its core, T-DM1 hinges on the targeted delivery of chemotherapy to cancer cells. By employing trastuzumab, a monoclonal antibody, the drug homes in on HER2 receptors, ubiquitous in HER2-positive breast cancer. Once the binding occurs, T-DM1 releases emtansine, a potent chemotherapy agent, directly into cancer cells. This dual-action approach maximizes treatment efficacy while minimizing the impact on healthy cells, illustrating T-DM1’s innovative and tailored approach to cancer care.



Prescription only

Pregnancy & Lactation